INVO Fertility, Inc.
INVO Fertility is a healthcare services and technology company focused on fertility care and expanding access to assisted reproductive technology. It acquires, establishes and operates fertility clinics and related businesses, and sells and distributes its INVOcell technology to third-party clinics. As of the date of filing, it operates four fertility clinics in the United States, offering services including in vitro fertilization (IVF) and intravaginal culture (IVC). Its clinic network also offers intrauterine insemination and other reproductive services. INVOcell is a medical device that enables fertilization and early embryo development to occur within the woman’s body using IVC. INVO earns money from fertility services provided through its clinics and from sales of the device. The company also provides management, administrative, laboratory and operational support to Family Beginnings in Indianapolis under a management services agreement.
No SEC Form 4 filings for $IVF in the last 30 days.
See all $IVF insider activity →INVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 INVO Fertility Announces a 1:4 Reverse Stock Split Effective Pre-Market Opening on October 30, 2026 SARASOTA, Fla., October 27, 2026 (GLOBE NEWSWIRE) – INVO Fertility, Inc. (“INVO”) (NASDAQ: IVF), a healthcare company focused on the establishment, acquisition and ope
INVO Fertility (NASDAQ: IVF) announced a 1-for-4 reverse stock split effective October 30, 2026. Registered holders will receive whole shares, while fractional shares held via brokers will be paid in cash. Post-split, the company will have approximately 1.19 million shares outstanding. The stock will continue trading under the symbol 'IVF'.
After-hours gainers included Profusa (PFSA) after a 1-for-4 reverse split, with shares outstanding cut to about 605,726. INVO Fertility (IVF) rose after Q2 results: revenue about $2.2M (+17% YoY) and net income about $0.9M. Amylyx (AMLX) traded higher ahead of Phase 3 LUCIDITY topline results on Aug 18, 2026. Vogenx (VOGX) and others also gained.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning IVF (INVO Fertility, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent IVF coverage spans corporate actions, earnings and financial news.
The reverse split will reduce share count, likely causing short‑term price volatility and potential upward pressure as the market adjusts.
The reverse split will reduce share float and increase per-share price, likely attracting institutional interest and reducing volatility.
Earnings beat on both top and bottom line is a near-term catalyst for momentum traders.
The earnings call highlights improving top-line and clinic-level profitability, but continued cash burn and dilution risk from a $15M equity purchase facility.
Q2 results show improving operating leverage at the clinic platform and a structural change (Birmingham fully owned) that can increase future earnings participation.
AlphAI scores every news story that mentions IVF with an AI model for sentiment and relevance, and aggregates insider trades from INVO Fertility, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
INVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 INVO Fertility Announces a 1:4 Reverse Stock Split Effective Pre-Market Opening on October 30, 2026 SARASOTA, Fla., October 27, 2026 (GLOBE NEWSWIRE) – INVO Fertility, Inc. (“INVO”) (NASDAQ: IVF), a healthcare company focused on the establishment, acquisition and ope
INVO Fertility (NASDAQ: IVF) announced a 1-for-4 reverse stock split effective October 30, 2026. Registered holders will receive whole shares, while fractional shares held via brokers will be paid in cash. Post-split, the company will have approximately 1.19 million shares outstanding. The stock will continue trading under the symbol 'IVF'.
After-hours gainers included Profusa (PFSA) after a 1-for-4 reverse split, with shares outstanding cut to about 605,726. INVO Fertility (IVF) rose after Q2 results: revenue about $2.2M (+17% YoY) and net income about $0.9M. Amylyx (AMLX) traded higher ahead of Phase 3 LUCIDITY topline results on Aug 18, 2026. Vogenx (VOGX) and others also gained.
INVO Fertility Inc reported Q2 2026 revenue of $2.18 million, up about 17% year over year, driven mainly by the full-quarter contribution from Family Beginnings in Indiana and organic growth. Clinic-level Adjusted EBITDA was about $333,000. Consolidated adjusted EBITDA stayed negative at about -$1.0 million. Cash was ~$3.7 million at June 30, 2026, and the company added a $15 million equity purchase facility.
INVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practice
INVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 ex10-1.htm EX-10.1 Exhibit 10.1 ANY MARKET PURCHASE AGREEMENT This Any Market Purchase Agreement (this “ Agreement ”), dated as of July 24, 2026 (the “ Execution Date ”), by and between INVO Fertility, Inc. , a Nevada corporation (the “ Company ”), and Alumni Capital LP
INVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001417926 0001417926 2026-06-23 2026-06-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor
INVO Fertility, Inc. (IVF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure 23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabiliti
INVO Fertility Inc (IVF) has been notified by Nasdaq's Listing Qualifications Department regarding a compliance issue due to its failure to submit its Annual Report on Form 10-K for the fiscal year ending December 31, 2025. This delay is attributed to complex accounting matters, leading to a low GF Score™ of 29/100, indicating significant financial and profitability challenges. The company, which operates in the medical devices and instruments industry with its INVOcell device, has a market capitalization of $3.1 million and is currently not generating profits, signaling caution for investors.
INVO Fertility (IVF) has received a notice from Nasdaq regarding its non-compliance with listing rules due to the late filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The delay is attributed to complex accounting matters, including tax provision, warrant, and variable interest entity accounting. Nasdaq's notice does not immediately impact the company's stock listing.
